What are the adverse reactions of Ruxolitinib Tablets/Jiekewei?

As a small molecule inhibitor targeting the JAK pathway, Ruxolitinib tablets/Ruxolitinib (Ruxolitinib) may also cause certain adverse reactions while improving the disease. Because it acts directly on hematopoietic and immune-related signaling pathways, its effects on the hematology and immune system are most common.

First, the adverse reactions related to myelosuppression are more prominent. After using ruxolitinib, some patients may experience anemia, thrombocytopenia or leukopenia. This is because the drug inhibits abnormal signaling pathways and also affects normal hematopoietic function. Therefore, it is necessary to regularly monitor blood routine during medication and adjust the dose based on the results to reduce the risk of hematological toxicity. Secondly, the increased risk of infection is also a common safety issue with this drug. Since theJAK pathway plays an important role in immune regulation, patients' resistance to viruses, bacteria and fungi may decrease after inhibition. Clinical attention needs to be paid to the occurrence of herpes zoster, respiratory infections, etc., and preventive measures should be taken when necessary.

In addition, some patients may experience headaches, dizziness, weight gain, elevated blood pressure, or mild abnormalities in liver function indicators. Most of these symptoms are mild to moderate and can be managed with monitoring and supportive management. In individual cases, long-term use may be associated with an increased risk of skin cancer, so it is recommended to strengthen skin health management and regular follow-up during treatment.

In general, the adverse reactions of ruxolitinib are mostly related to its mechanism of action, but most of them are within the controllable range. In clinical applications, doctors will adjust the dosage or take combined interventions based on the patient's tolerance and disease status to strike a balance between efficacy and safety. For patients, regular monitoring and communication with their doctor are keys to using this drug safely.

Reference materials:https://www.jakavi.com/